Jade Biosciences(NASDAQ) JBIO

Current Price$20.02

Market Cap$1.22B

Since IPO (2025)+98%

5 Year-61%

1 Year+141%

1 Month-8%

Jade Biosciences last closing stock price
Metric	Price	Date
Last close	USD 20.08	2026-07-24

Jade Biosciences stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-3.74%	USD 20.86	2026-07-17
1 month	-8.31%	USD 21.90	2026-06-24
3 month	-19.62%	USD 24.98	2026-04-24
Year to date	+30.14%	USD 15.43	2025-12-31
1 year	+141.06%	USD 8.33	2025-07-24
3 year	-66.88%	USD 60.63	2023-07-25
5 year	-61.41%	USD 52.04	2021-07-23
Since inception	+98.03%	USD 10.14	2025-04-29

Jade Biosciences Financials at a Glance

Market Cap

$1.22B

Revenue (TTM)

$0.00

Net Income (TTM)

-$129.61M

EPS (TTM)

-$2.99

P/E Ratio

-6.72

Dividend

$0.00

Beta (Volatility)

0.16 (Low)

Dividend

$0.00

Beta (Volatility)

0.16 (Low)

Price

$20.02

Volume

15,792

Open

$19.64

Price

$20.02

Volume

15,792

Open

$19.64

Previous Close

$20.02

Daily Range

$19.05 - $20.08

52-Week Range

$6.67 - $28.00

Estimated Earnings Date

Aug 12, 2026

Dividend

$0.00

Beta (Volatility)

0.16 (Low)

Price

$20.02

Volume

15,792

Open

$19.64

Previous Close

$20.02

Daily Range

$19.05 - $20.08

52-Week Range

$6.67 - $28.00

Estimated Earnings Date

Aug 12, 2026

JBIO News

Jade Biosciences Posts Wider Loss in Q2

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Jade Biosciences

Jade makes new medicines for people whose immune systems attack their own bodies. These treatments help patients with serious kidney problems and other long-term health issues. The company aims to make drugs that are easier to use and more effective than current options.

What is Jade Building?

JADE101: A monoclonal antibody (mAb), or lab-made protein, designed to treat IgA nephropathy (IgAN), a chronic kidney disease. It targets the APRIL protein to stop harmful antibody production.
JADE201: An experimental treatment for rheumatoid arthritis and other autoimmune disorders. This drug targets the BAFF-R receptor to clear out harmful B cells from the immune system.
JADE301: A preclinical program focused on a specific, undisclosed biological pathway to expand the company's treatment portfolio.

Alliances and Agreements

Entered into a research agreement with Paragon Therapeutics, Inc. in July 2024 to discover and develop new antibody treatments.
Secured exclusive worldwide licenses from Paragon Therapeutics, Inc. for JADE101 in October 2024 and JADE201 in October 2025.
Partnered with WuXi Biologics and Patheon Biologics LLC in early 2025 to handle the manufacturing and testing of its drug candidates.
Launched its first human clinical trial for JADE101 in August 2025, marking the company's shift into a clinical-stage business.

What Makes Their Science Different

Jade uses half-life extension technology to make its treatments last longer in a patient's body. This approach allows for less frequent injections, making it more convenient for people with chronic illnesses to manage their health.

A Look at the Numbers

Revenue remained at zero for the fiscal year ended December 31, 2025, as products are still in development.
Operating income was -$35 million in Q4 2025, a loss that worsened by 446.3% from -$6.4 million in Q4 2024.
Net income reached -$67.6 million in Q4 2025, declining 1144.6% from a loss of -$5.4 million in the previous year.
Market capitalization grew to $1.1 billion in Q4 2025, representing a 1322% increase from $76.8 million in Q4 2024.
Operating cash flow was -$33.6 million in Q4 2025, which worsened by 204.6% compared to the -$11 million reported in Q4 2024.

The Road Ahead

Jade has evolved from a discovery-focused startup into a clinical-stage biotech firm. Its future depends on the clinical trial results of its licensed antibody programs for autoimmune diseases.

AI Generated • May 1, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Tom Frohlich, MBA

Website

www.jadebiosciences.com

Headquarters

Waltham, MA 02453, US

JBIO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-51.34%

Return on Capital

-34.07%

Return on Assets

-40.57%

Earnings Yield

-14.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.22B

Shares Outstanding

60.86M

Volume

15.79K

Avg. Volume

1.04M

Financials (TTM)

Gross Profit

-$9.00K

Operating Income

-$133.60M

EBITDA

-$129.50M

Operating Cash Flow

-$116.39M

Capital Expenditure

-$196.00K

Free Cash Flow

-$116.59M

Cash & ST Invst.

$311.30M

Total Debt

$679.00K

Jade Biosciences Performance Analysis

Jade Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

Jade Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

Jade Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -73.67	123.5%
2023	2023-12-31	USD -100.38	36.3%
2024	2024-12-31	USD -85.26	-15.1%
2025	2025-12-31	USD -4.06	-95.2%

Jade Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	62.8%
Q3	2025-09-30	43.4%
Q4	2025-12-31	-1.6%
Q1	2026-03-31	-7.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$9.00K

-125.0%

Gross Margin

0.00%

N/A

Market Cap

$1.22B

N/A

Market Cap/Employee

$22.22M

N/A

Employees

N/A

Net Income

-$40.37M

-1503.2%

EBITDA

-$40.34M

-1504.7%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$311.30M

+308.5%

Total Debt

$679.00K

+117.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$679.00K

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-40.57%

N/A

Return on Invested Capital

-44.96%

N/A

Free Cash Flow

-$24.08M

-118.0%

Operating Cash Flow

-$24.08M

-118.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

TECXTectonic Therapeutic, Inc.

TECXTectonic Therapeutic, Inc.$30.37-3.92%

CTNMContineum Therapeutics, Inc.

CTNMContineum Therapeutics, Inc.$14.06-2.16%

SLNSilence Therapeutics plc

SLNSilence Therapeutics plc$11.02-3.76%

XOMAXOMA Royalty Corp.

XOMAXOMA Royalty Corp.$40.17+0.00%

KYTXKyverna Therapeutics, Inc.

KYTXKyverna Therapeutics, Inc.$7.41+1.65%

LYELLyell Immunopharma, Inc.

LYELLyell Immunopharma, Inc.$12.63-1.17%

ACIUAC Immune S.A.

ACIUAC Immune S.A.$2.23-0.45%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

TAT&T

TAT&T$24.13+0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$11.93+0.09%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.00-0.03%

Questions About JBIO

What is the current price of Jade Biosciences?

Jade Biosciences is trading at $20.02 per share.

What is the 52-week range for Jade Biosciences?

Over the past 52 weeks, Jade Biosciences has traded between $6.67 and $28.00.

How much debt does Jade Biosciences have?

As of the most recent reporting period, Jade Biosciences reported total debt of $679.00K.

How much cash does Jade Biosciences have on hand?

Jade Biosciences reported $55.09M in cash and cash equivalents in its most recent financial results.

What is Jade Biosciences’s dividend yield?

Jade Biosciences does not currently have a dividend yield.

Jade Biosciences(NASDAQ) JBIO

Jade Biosciences Financials at a Glance

JBIO News

Jade Biosciences Posts Wider Loss in Q2

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Jade Biosciences

What is Jade Building?

Alliances and Agreements

What Makes Their Science Different

A Look at the Numbers

The Road Ahead

JBIO Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Jade Biosciences Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About JBIO

What is the current price of Jade Biosciences?

What is the 52-week range for Jade Biosciences?

How much debt does Jade Biosciences have?

How much cash does Jade Biosciences have on hand?

What is Jade Biosciences’s dividend yield?

Premium Investing Services